You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric

Showing 1 - 25 of 1,681
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Recurrent or Metastatic Bladder Cancer Trial in Shanghai (Chimeric exosomal tumor vaccines)

Recruiting
  • Recurrent or Metastatic Bladder Cancer
  • Chimeric exosomal tumor vaccines
  • Shanghai, China
    Fudan University Pudong Medical Center
Sep 26, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Renal Cell Carcinoma, Kidney Tumor, Renal Cancer Trial in New York (Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250))

Completed
Has Results
  • Renal Cell Carcinoma
  • +3 more
  • Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Study of Participants Who ReceivedAllogeneic CAR T-Cell Product

Recruiting
  • Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
    • Culver City, California
      Science 37, Inc.
    Apr 10, 2023

    Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

    Not yet recruiting
    • Multiple Myeloma
    • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Jan 13, 2023

    Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

    Not yet recruiting
    • Neuroendocrine Tumor (NET)
    • Colorectal Cancer (CRC)
    • CHM-2101 CAR-T cells
    • (no location specified)
    Sep 20, 2023

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +6 more
    • CEA-targeted CAR-T cells
    • Taiyuan, Shanxi, China
    • +1 more
    Aug 24, 2023

    Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

    Not yet recruiting
    • Small Cell Lung Cancer Extensive Stage
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • LB2102
    • (no location specified)
    Jan 10, 2023

    Solid Tumor Trial (HER2-E-CART cells)

    Not yet recruiting
    • Solid Tumor
    • HER2-E-CART cells
    • (no location specified)
    Feb 16, 2023

    Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

    Not yet recruiting
    • Follicular Lymphoma
    • Axicabtagene Ciloleucel
    • +5 more
    • (no location specified)
    Sep 21, 2023

    Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

    Recruiting
    • Lupus Nephritis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Denver, Colorado
    • +1 more
    Jul 7, 2023

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +7 more
    • CEA-targeted CAR-T cells
    • Wuhu, Anhui, China
      The First Affiliated Hospital of Wannan Medical College
    Nov 9, 2023

    Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

    Recruiting
    • Acute Myeloid Leukemia
    • Anti-CLL1 CART cells
    • Kunming, Yunnan, China
      No.212 Daguan Road, Xishan District
    Nov 23, 2022

    Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)

    Recruiting
    • Colorectal Cancer
    • +6 more
    • CEA-targeted CAR-T cells
    • Hangzhou, Zhejiang, China
    • +1 more
    Sep 18, 2023

    Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

    Recruiting
    • Hairy Cell Leukemia
    • Hairy Cell Leukemia Variant
    • CD22CART cell infusion
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 25, 2023

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

    Recruiting
    • Refractory Multiple Myeloma
    • Relapsed Multiple Myeloma
    • Manufactured Anti-BCMA CAR-T cells
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Jan 6, 2023

    Japanese Encephalitis Trial in Hoa Binh (Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®))

    Completed
    Has Results
    • Japanese Encephalitis
    • Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
    • Hoa Binh, Vietnam
      Preventive Medicine Centre of Hoa Binh Province
    Mar 21, 2022

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

    Recruiting
    • Immunotherapy
    • Multiple Myeloma
    • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Dec 14, 2022

    Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 10, 2023